Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 19, 2017. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction data:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.4042 per share for all reported transactions.
- Transaction Date: April 18, 2017.
- Exchange: London Stock Exchange (XLON).
- Total Volume: Approximately 8,847.63 shares acquired across 10 individuals.
Material Changes
The filing does not report material changes to the company's financial position or operations. It reports routine share acquisitions resulting from the re-investment of dividends paid to shareholders on April 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are standard dividend reinvestment activities.
Important Facts for Investors
- Transaction Nature: All reported share purchases were automatic acquisitions via dividend reinvestment, not open-market purchases initiated by the executives.
- Participants: Transactions involved senior leadership including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and Presidents of Global Vaccines, Global Pharmaceuticals, and R&D.
- Price Consistency: All transactions executed at the identical price of £16.4042, consistent with a single dividend reinvestment event.
- Scope: This filing is a regulatory disclosure of insider trading activity and does not contain financial performance data for the company.